Bulletin
Investor Alert

Topics

Food and Drug Administration

2:42 a.m. Oct. 5, 2021 - By Ciara Linnane
J&J amends FDA EUA submission for COVID-19 booster with data showing 94% protection against moderate to severe illnessJohnson & Johnson said Tuesday it has submitted an amendment to the emergency use authorization it's seeking from the U.S. Food and Drug Administration for a booster shot of its COVID-19 vaccine with additional data showing it increased protection to 94% against moderate to severe or critical COVID-19 in the U.S. The submission includes recent data from a Phase 3 trial that found the booster given 56 days after primary dose provided 94% protection against symptomatic illness in moderate to severe/critical COVID-19 and 100% protection against severe/critical COVID-19, at least 14 days post-booster vaccination. The submission further includes Phase 1/2 data that shows a booster given six months after the single shot vaccine increases antibody levels nine-fold a week after the booster that climbs to 12-fold higher four weeks after the booster. J&J is planning to submit the data to other regulators, to the World Health Organization and National Immunization Technical Advisory Groups. Shares were up 0.5% premarket and have gained 1.2% in the year through Monday, while the Dow Jones Industrial Average has gained 11%.
2:42 a.m. Sept. 21, 2021 - By Ciara Linnane
Johnson & Johnson says Phase 3 trial data confirms 'strong and long-lasting' protection from COVID-19 vaccine Johnson & Johnson said Tuesday data from a Phase 3 trial and real-world evidence confirm that its single-shot COVID-19 vaccine offers strong and long-lasting protection against hospitalization and death. The company said further data shows that a booster shot offers increased protection. Data shows 94% protection in the U.S. with a booster given at two months, a four-fold increase in antibodies when given at two months and a 12-fold increase when given at six months. "The safety profile of the vaccine remained consistent and was generally well-tolerated when administered as a booster," the company said in a statement. The company has submitted data from the trial to the U.S. Food and Drug Administration and other regulators, the World Health Organization and National Immunization Technical Advisory Groups (NITAGs) worldwide. The Phase 3 trial included 390,000 people who got the J&J one-shot vaccine versus about 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code and comorbidities and predictors for COVID-19 infection severity. The trial was conducted from March to late July 2021. Shares rose 1.1% premarket and have gained 4% in the year through Monday's close, while the Dow Jones Industrial Average has gained 11% and the S&P 500 has gained 16%.
3:15 a.m. Sept. 20, 2021 - By Ciara Linnane
Pfizer and BioNTech say COVID-19 vaccine safe and effective in children aged 5 to 11Pfizer Inc. and German partner BioNTech SE on Monday announced positive results in a Phase 2/3 trial of their COVID-19 vaccine in children aged 5 to 11, and said the vaccine was safe, well tolerated and produced "robust" neutralizing antibody response. The companies said participants in the trial were given a two-dose regimen of 10 ug administered 21 days apart, a smaller dose than the 30 ug given to people aged 12 and older. "The antibody responses in the participants given 10 ug doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunized with 30 ug doses," the companies said in a joint statement. "The 10 ug dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age. These are the first results from a pivotal trial of a COVID-19 vaccine in this age group." The companies are planning to submit the data to the Food and Drug Administration and the European Medicines Agency, as well as to other regulators around the world as soon as possible. Results from a trial involving children younger than 5 are expected "as soon as later this year," said the statement. "Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. -- underscoring the public health need for vaccination," said Pfizer CEO Albert Bourla in the statement. There were 2,268 participants in the trial. Shares of both companies were lower premarket, caught up in a broad market rout sparked by fears of a default by Chinese property developer China Evergrande. Pfizer shares have gained 19% in the year to date, while BioNTech has gained 341%. The SPDR S&P Biotech ETF has fallen 6% and the S&P 500 has gained 18%.
3:27 a.m. Sept. 9, 2021 - By Ciara Linnane
Moderna says it has about $15 billion in cash, working on combined COVID/seasonal flu boosterModerna Inc. said Thursday it had a cash position of about $15 billion as of Aug. 31. The company made the disclosure as it offered an update on its line of product candidates based on mRNA technology, that includes a vaccine against COVID-19, the first Moderna product to win authorization from the U.S. Food and Drug Administration. In a statement released ahead of an R&D day, the company highlighted a new product candidate that would combine a COVID-19 booster with a seasonal flu booster vaccine. The company recently submitted an application to the FDA for approval of its COVID booster shot, and said it saw "robust antibody responses" in a Phase 2 study. Overall, the company has 37 programs in development across 34 development candidates, including 22 in current clinical studies. Shares were flat premarket, but have gained 305% in the year to date, while the SPDR S&P Biotech ETF has fallen 6% and the S&P 500 has gained 20%.
4:58 a.m. Aug. 27, 2021 - By Tomi Kilgore
Cassava's stock tumbles again, after Quanterix said it 'did not' prepare data charts presented by Cassava, that are under disputeQuanterix Corp. said that while it was previously engaged by Cassava Sciences Inc. to perform sample testing, the digitized biomarker analysis company said it, or its employees, "did not interpret the test results or prepare the data charts" presented by Cassava to the Alzheimer's Association International Conference (AAIC) in July, or otherwise. Earlier this week, to a request the Food and Drug Administration halt clinical studies of Cassava's Alzheimer's treatment because of , Cassava had said that data from Alzheimer's patients were generated by Quanterix. The news of the halt request had sent Cassava's stock plunging 39.9% in two days through Thursday. Quanterix's stock dropped 9.2% on Thursday, after losing 1.5% on Wednesday. In Friday's statement, Quanterix said it is "widely recognized for its commitment to business integrity and to upholding the highest standards of quality." Quanterix's stock rose 4.5% in premarket trading, while Cassava shares tumbled 21.2%
2:37 a.m. Aug. 25, 2021 - By Tomi Kilgore
Cassava Sciences stock tumbles, and company responds to allegations disputing trial dataCassava Sciences Inc. responded Wednesday to allegations posted overnight regarding the "accuracy and integrity" of trial data for its treatment of Alzheimer's disease, saying it believed the claims are "false and misleading." Cassava's stock had rallied 1.9% on Tuesday, and 16.4% over the past three days, with the company saying early Tuesday that it reached agreement with the Food and Drug Administration under a Special Protocol Assessment (SPA) for its Phase 3 studies of oral simufilam for the treatment of Alzheimer's patients. The stock then tumbled after the bell -- it was down 17.8% in Wednesday's premarket -- after requesting the FDA halt the current clinical studies of simufilam, disputing the validity of clinical biomarker data, the integrity of western blot analyses and the integrity of analyses involving human brain tissue. "As a science company, we champion facts that can be evaluated and verified," said Chief Executive Remi Barbier. "This helps people make informed choices. It is important for stakeholders to separate fact from fiction, which is why we wish to address allegations head-on." Cassava with the "fact" that data from Alzheimer's patients were generated by an independent company, Quanterix Corp., and said western blot analysis is "foundational," and a standard lab technique used to detect a protein of interest. The stock has rocketed 1,627.7% year to date through Tuesday, while the S&P 500 has gained 19.4%.
4:54 a.m. July 16, 2021 - By Joseph Walker
Cleveland Clinic, Mount Sinai and Providence won’t give Biogen’s new Alzheimer’s drug The three hospital operators are holding off on administering Aduhelm amid a debate over its effectivenessThree large hospitals are declining to administer Biogen Inc.’s new Alzheimer’s treatment, Aduhelm, the latest rupture to emerge from the Food and Drug Administration’s controversial approval of the drug last month.
9:36 a.m. July 9, 2021 - By Ciara Linnane
Biogen shares fall on report FDA head seeking investigation of her agency's approval of Alzheimer's drugBiogen Inc. shares slid 3% Friday, after a STAT report that the acting head of the U.S. Food and Drug Administration is calling for a federal investigation into her own agency's approval of a treatment for Alzheimer's disease, a month after the decision irked lawmakers, doctors and pubic health advocates and led members of an independent committee associated with the FDA to step down. In a letter, Acting Commissioner Janet Woodcock asked the Office of the Inspector General to investigate interactions between FDA staff and Biogen in the run-up to the approval of the drug Aduhelm, The agency cited reporting by STAT that said FDA officials had worked closely with Biogen to get the drug to market. "There continue to be concerns raised ... regarding contacts between representatives from Biogen and FDA during the review process, including some that may have occurred outside of the formal correspondence process," Woodcock wrote in a letter to acting Inspector General Christi Grimm. On Thursday, Biogen announced an updated label for Aduhelm that limited the patients who qualify for the drug to those with "mild cognitive impairment or mild dementia stage of disease" rather than a broader group of people diagnosed with dementia because that is the group of people who were studied in the clinical trials. The FDA has been criticized for approving Aduhelm with what some consider is questionable clinical data and Biogen for how the drug is priced, at $56,000 for a year of treatment. Biogen shares have gained 47% in the year to date, while the SPDR S&P Biotech ETF has fallen 5% and the S&P 500 has gained 15%.
3:55 a.m. June 11, 2021 - By Tomi Kilgore
Orphazyme stock losing half its value premarket, after rocketing fourfold the day beforeShares of Orphazyme A/S plunged 50.2% in active premarket trading Friday, , after the Denmark-based biopharmaceutical company said overnight that wasn't aware of any reason for the recent "extreme volatility." Trading volume was already up to 4.1 million shares before Friday's open, compared with the full-day average over the past 30 days of about 286,000 shares, according to FactSet On Thursday, the stock had soared as much 1,387% intraday before closing up 301.5% on volume of 7.9 million shares, and was halted a total of 22 times for volatility during the day. "The company is not aware of any material change in its clinical development programs, financial condition or results of operations that would explain such price volatility or trading volume that has occurred since June 10, 2021," the company said in a statement. "Investors who purchase the company's ADS or shares may lose a significant portion of their investments if the price of such securities subsequently declines." The company's applications for arimoclomol for Niemann-Pick disease type C are under priority review with the U.S. Food and Drug Administration, with an expected action date of June 17. Even with the previous day's surge, the stock has gained 62.9% over the past three months through Thursday, while the S&P 500 has gained 7.6%.
2:42 a.m. April 19, 2021 - By Ciara Linnane
Emergent BioSolutions says it has agreed with FDA not to manufacture new material at Baltimore facility Drug contract company Emergent BioSolutions Inc. said Monday it has made an agreement with the U.S. Food and Drug Administration not to manufacture any new material at its Bayview facility in Baltimore. The FDA started an inspection of the plant last week, after Johnson & Johnson found Emergent workers had confused ingredients for its COVID-19 vaccine with ones used in making the vaccine developed by AstraZeneca PLC and Oxford University. J&J made the discovery in a batch that had not been distributed and immediately took over the making of its vaccine and imposed its own experts and technicians to oversee it. Emergent agreed it would shift manufacturing of the AstraZeneca vaccine elsewhere. Emergent has also agreed to quarantine existing material at the plant pending completion of the FDA inspection. Emergent shares were down 0.9% premarket, and have fallen 13% in the year to date, while the S&P 500 has gained 11.4%.
4:32 a.m. April 7, 2021 - By Tomi Kilgore
Anthem to provide employees with an incentive to be fully vaccinated against COVID-19Anthem Inc. said Wednesday it will provide an incentive to any of its employees who are fully vaccinated against COVID-19. The health insurer said the incentive will be in the form of a one-time credit toward medical premiums or a donation to the Anthem Cares Fund that helps support fellow employees in need, at the employees choice. "Anthem is committed to empowering our associates to live a healthy lifestyle, therefore it was important that we provided an incentive to those who receive the COVID-19 vaccination. I am impressed and grateful for everything our associates have done and continue to do for the customers and communities we serve," said Chief Human Resources Officer Leah Stark. There are currently three COVID-19 vaccines that have been granted emergency use authorization by the Food and Drug Administration, two-dose vaccines from Pfizer Inc. and partner BioNTech SE and Moderna Inc. , and Johnson & Johnson's one-dose vaccine. Anthem's stock, which was indicated down 0.4% in premarket trading, has rallied 9.7% year to date while the S&P 500 has gained 8.5%. (This replaces an earlier item that removes the dollar amount of the incentive provided by the company, after the company said the amount noted in a previous release resulted from a "publishing mistake.")
4:40 a.m. March 26, 2021 - By Ciara Linnane
GlaxoSmithKline and Vir Biotech seek FDA emergency authorization for COVID antibody treatmentGlaxoSmithKline PLC and Vir Biotechnology Inc. said Friday they have submitted to the U.S. Food and Drug Administration an application for emergency use authorization for their antibody treatment for mild-to-moderate COVID-19 in adults and adolescents aged 12 and older who are at risk of hospitalization or death. The companies said early data from a Phase 3 trial found the treatment showed an 85% reduction in hospitalization or death compared to placebo. There were 583 patients enrolled in the trial. Vir shares slid 0.8% premarket, but have gained 97% in the year to date, while the S&P 500 has gained 4%.
4:35 a.m. March 24, 2021 - By Tomi Kilgore
Second Sight Medical stock tumbles after private placement of stock at 46% discountShares of Second Sight Medical Products Inc. tumbled 25% to pace all premarket decliners on Wednesday, after the implantable visual prosthetics company announced a large private placement of common stock. The share sale comes after more than 6-fold month to date through Tuesday, after the company's Argus 2s Retinal Prosthesis System was . The company said earlier Wednesday that it will issue 4.65 million shares, which represents about 20% of the shares outstanding, at a price of $6.00, which is 45.5% below Tuesday's closing price of $11.01, for gross proceeds of $27.9 million. The company expects to use the proceeds for working capital. The stock has soared 488.8% year to date through Tuesday, while the S&P 500 has gained 4.1%.
7:33 a.m. March 4, 2021 - By Tomi Kilgore
Moderna, IBM explore blockchain tech, AI to support 'smarter' management of COVID-19 vaccinesModerna Inc. and International Business Machines Corp. announced Thursday plans to work together to find technologies to support "smarter COVID-19 vaccine management." The technologies the companies will explore include artificial intelligence, blockchain and hybrid cloud, the companies said. "Moderna is committed to working with a coalition of partners to increase education and awareness of the importance of vaccination to help defeat COVID-19," said Michael Mullette, a managing director of North America commercial operations at Moderna. "We look forward to working with IBM to apply digital innovations to build connections between organizations, governments, and individuals to instill confidence in COVID-19 vaccines." Moderna's stock rose 1.6% in midday trading and IBM shares fell 0.7%, while the Dow Jones Industrial Average gained 118 points, or 0.4%. Moderna currently has one of three COVID-19 vaccines granted emergency use authorization by the Food and Drug Administration, the others being from Pfizer Inc. and BioNTech SE and Johnson & Johnson .
9:47 a.m. Feb. 23, 2021 - By Tomi Kilgore
Meridian Bioscience issues correction: It can't ship its Revogene SARS-CoV-2 test until EUA is grantedMeridian Bioscience Inc. issued a statement Tuesday afternoon, to correct a statement made earlier regarding its SARS-CoV-2 molecular diagnostic test on its Revogene platform. The stock dropped 8.7%, and has now tumbled 30.0% since it closed on Feb. 11 at the highest price since October 2008. After speaking with the Food and Drug Administration mid-morning Tuesday, the company said it will not be able to distribute its Revogene SARS-CoV-2 test until the test receives Emergency Use Authorization approval from the FDA. Earlier Tuesday, the company had said it would resume shipping of the tests once it notifies the FDA of its intent to re-submit an EUA application. The company said Tuesday that it had decided to withdraw its EUA application following further discussions with the FDA, which comes a week after the company said the FDA requested additional information on the test. Despite the recent selloff, Meridian's stock has still climbed 19.5% over the past three months, while the S&P 500 has gained 7.7%.
4:19 a.m. Jan. 26, 2021 - By Ciara Linnane
Moderna on track to deliver 200 million doses of its COVID vaccine to U.S. govt by end-JuneModerna Inc. said Tuesday it is on track to deliver 100 million doses of its COVID-19 vaccine to the U.S. government by end-March and to deliver 200 million doses by end-June. The Cambridge, Mass.-based biotech said it has already delivered more than 30 million doses of the vaccine to the U.S. government. About 10.1 million doses of the vaccine have by now been administered in the U.S., the company said, citing Centers for Disease Control and Prevention data. The vaccine was granted emergency use authorization by the U.S. Food and Drug Administration on Dec. 18, shortly after a separate vaccine developed by Pfizer Inc. and its German partner BioNTech SE won the same authorization. The U.S. government has an option to purchase up to 300 million doses of the Moderna vaccine. The vaccine has also been authorized for use in Canada, Israel, the European Union, the U.K. and Switzerland. Moderna shares were down 1.2% premarket, but have gained 596% in the last 12 months, while the SPDR S&P Biotech ETF has gained 73% and the S&P 500 has gained 17%.
4:16 a.m. Jan. 12, 2021 - By Tomi Kilgore
Uber, Moderna to collaborate on supporting COVID-19 vaccine uptakeUber Technologies Inc. and Moderna Inc. said Tuesday they will collaborate to explore ways to support the uptake of COVID-19 vaccines. The ridesharing and delivery company and the biotech said they will work together to provide "credible information" on vaccine safety through Uber's in-app messaging, and will look to identify opportunities to broaden access to COVID-19 vaccines. Moderna's COVID-19 vaccine was authorized in December for emergency use by the Food and Drug Administration, along with a vaccine from Pfizer Inc. and BioNTech SE , but the . "As part of our commitment to help address COVID-19, Moderna will be working with a coalition of partners to educate, build trust around and increase awareness of the importance of vaccination in those communities significantly impacted by the pandemic," said Moderna Chief Executive Stéphane Bancel. "We look forward to combining our expertise with Uber's capabilities and platform to support this important effort." Uber's stock rose 1.5% in premarket trading Tuesday and Moderna shares advanced 0.8%, while futures for the S&P 500 edged up 0.2%.
10:19 a.m. Jan. 5, 2021 - By Ciara Linnane
January will be worst month for U.S. pandemic so far with post-holiday travel cases seen surging U.S. sets fresh record for hospitalizations and Los Angeles County says a COVID-19 patient is dying every 15 minuteshe number of global cases of the coronavirus-borne illness COVID-19 edged toward 86 million on Tuesday and the U.S. set yet another record for hospitalizations, as experts warned that January will likely be the worst month of the pandemic so far due to a surge in new infections after holiday travel.
10:56 a.m. Jan. 4, 2021 - By Ciara Linnane
U.S. heads toward 21 million COVID-19 cases and 353,000 deaths as vaccine program continues to lag all targets ‘Last mile’ vaccine distribution has been far slower than required, ‘with millions of doses still sitting on the shelves,’ says Raymond James analystThe global case tally for the coronavirus-borne illness COIVID-19 climbed above 85 million on Monday, as the U.S. headed toward 21 million cases and 353,000 deaths, as the vaccine program continued to advance with fits and starts and to lag all early targets.
2:05 a.m. Dec. 29, 2020 - By Ciara Linnane
Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion Companies are also seeking approval for drug as treatment for unmet women’s health needsShares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women’s health in a deal worth up to $4.2 billion in upfront and potential milestone payments.
4:33 a.m. Dec. 28, 2020 - By Ciara Linnane
UPDATE: Myovant shares soar 20% premarket on news of Pfizer cancer drug deal worth up to $4.2 billionShares of Myovant Sciences soared 20% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health in a deal worth up to $4.2 billion in upfront and potential milestone payments. Myovant will receive an upfront payment of $650 million to develop relugolix, a once-daily, oral gonadotropin-releasing hormone receptor antagonist for use in oncology and women's health in the U.S. and Canada. Pfizer will have the exclusive right to commercialize relugolix in oncology outside the U.S. and Canada, excluding some Asian countries. Myovant is one of five companies under the Sumitovant umbrella. "Myovant and Pfizer will jointly develop and commercialize ORGOVYX(TM) (relugolix) in advanced prostate cancer and, if approved, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women's health in the U.S. and Canada," the companies said in a joint statement. The U.S. Food and Drug Administration approved Orgovyx on Dec. 18 as a treatment for advanced prostate cancer. Pfizer shares were slightly higher premarket and have gained 0.4% in the year to date, while the S&P 500 has gained 15%.
2:18 a.m. Dec. 7, 2020 - By Quentin Fottrell
Joe Biden’s pandemic plan: Restore Obamacare, mandatory masks, paid sick leave and free COVID-19 tests The President-elect said: ‘Dealing with the coronavirus pandemic is one of the most important battles our administration will face’The President-elect said: ‘Dealing with the coronavirus pandemic is one of the most important battles our administration will face.’
4:08 a.m. Dec. 4, 2020 - By Ciara Linnane
Eli Lilly and UnitedHealth to study Lilly's antibody treatment bamlanivimab in high-risk COVID patients Eli Lilly & Co. and UnitedHealth Group Inc. said Friday they are joining forces for a study of Lilly's bamlanivimab in high-risk, COVID-19 infected patients. Bamlanivimab is an antibody treatment that recently won U.S. Food and Drug Administration emergency use authorization as a treatment for mild to moderate COVID-19 patients, who are at high risk of getting a severe case of the virus and/or requiring hospitalization. "The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions with a goal of reducing the severity of illness and hospitalizations ," the companies said in a joint statement. "Larger pragmatic studies in diverse populations can help us further understand the efficacy and safety of SARS-CoV-2 neutralizing antibodies in real world settings," said Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories. Eli Lilly shares were not active premarket, while UnitedHealth was slightly higher.
2:31 a.m. Dec. 1, 2020 - By Tomi Kilgore
Pfizer, BioNTech apply for CMA in Europe for COVID-19 vaccine candidateShares of Pfizer Inc. rallied 2.8% while Germany-based BioNTech SE dropped 2.5% in premarket trading Tuesday, after the company said they submitted their COVID-19 vaccine candidate BNT162b2 for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA). If the EMA recommends granting a CMA, that could lead to use of BNT162b2 in Europe before the end of 2020. The companies had to the Food and Drug Administration on Nov. 20. On Monday, Moderna Inc. , and said it will apply for CMA with the EMA. Shares of Pfizer have gained 9.7% over the past three months and BioNTech's stock has rocketed 114.9%, while the S&P 500 has edged up 2.7%.
4:58 a.m. Nov. 16, 2020 - By Quentin Fottrell
‘Help is coming — and it’s coming soon’: Dr. Fauci outlines when COVID-19 vaccine will be available to all Americans ‘When we get both of those things together — vaccine and public health measures — that would really be a game changer,’ says government’s top infectious-diseases expertInfectious disease expert Dr. Anthony Fauci said: ‘When we get both of those things together — vaccine and public health measures — that would really be a game changer.’
9:47 a.m. Nov. 9, 2020 - By Quentin Fottrell
Joe Biden announces his COVID-19 task force The team of public-health experts will advise the Biden administration and the transition’s COVID-19 staffThe team of public-health experts will advise the Biden administration and the transition’s COVID-19 staff.
5:36 a.m. Oct. 31, 2020 - By Ciara Linnane
Coronavirus update: U.S. counts almost 100,000 cases in new one-day record; The Lancet says Trump pandemic response is ‘disastrous’ USA Today poll finds most Americans disapprove of Trump’s campaign rallies, prefer Biden’s more discreet approachThe U.S. death toll from the coronavirus illness COVID-19 headed toward 230,000 on Saturday and cases topped 9 million after more than 99,000 infections were counted in a record one-day tally, with infections climbing in all swing states just days ahead of the presidential election.
7:46 a.m. Oct. 29, 2020 - By Ciara Linnane
Coronavirus update: U.S. continues to set new case records as Trump remains insistent that U.S. has ‘rounded the corner’ New COVID-19 cases are rising in 47 states, and 27 states recorded 1,000 or more new diagnoses in the last 24 hoursThe U.S. death toll from the coronavirus illness COVID-19 edged closer to 228,000 on Thursday and more than 81,000 new infections were recorded in a single day, pushing the seven-day tally to record highs.
Browse topics:

Filter results by

Location

Us (353)

Europe (45)

Eu (34)

Asia Pacific (30)

China (24)

Canada (7)

Link to MarketWatch's Slice.